Valeant Pharmaceuticals International $4.565 Billion Term Loan Facility and $1.225 Billion Revolving Credit Facility

Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) and Valeant Pharmaceuticals International in connection with a $4.565 billion senior secured term loan and $1.225 billion senior secured revolving credit facility. The proceeds of the secured term loan were used to refinance Valeant’s existing secured term loan facility. The secured revolving credit facility will be used for general corporate purposes.

Valeant is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.

The Davis Polk finance team included partner Jason Kyrwood, counsel Hilary Dengel and associates Nathan Huynh and Jeff Najjar. Partner Christophe Perchet and associates Géraldine Fromage and Daniel Arroche provided French law advice. Partner Nick Benham and associates Patrick Ryan and Li Lin provided English law advice. Members of the Davis Polk team are based in the New York, London and Paris offices.